ERBB2 and breast carcinoma: One of several retrospective trials investigating the benefit of continuation of trastuzumab was a multicenter, international study which identified 105 patients with metastatic HER2-positive breast cancer who had received trastuzumab after documented progression on a trastuzumab-containing regimen [11].